|
|
|
| Effect of Danhong Injection combined with Valsartan on Efficacy and Related Factors in Patients with Chronic Renal Failure |
| WANG Liping, WU Gang, LIAO Zhimin, et al |
| The Second People's Hospital of Liangshan, Sichuan Xichang 615000, China |
|
|
|
|
Abstract Objective: To study the effect of Danhong injection combined with valsartan on chronic renal failure and its related factors. Methods: 90 patients of chronic renal failure received therapy from March 2015 to March 2016 in our hospital were selected as research objects. According to the draw method divided into control group(n=45) and treatment group(n=45). Two groups of patients were treated with conventional treatment. The control group was treated with valsartan, 80mg per day, once a day. While the treatment group, on the basis of control group, treated with Danhong injection, 40mg per day, Add 5% glucose injection 200mL and mix intravenously, once a day. The two groups were treated for one month. Then treatment effect, clinical symptom score, renal function index, the level of 24 h urinary albumin (UAE), blood urea nitrogen (BUN), serum creatinine (SCr), the serum level of TGF-1, beta 1, VEGF, MCP-1, ANG II of two groups were compared. Results: The total effective rate of the treatment group was significantly higher than that of the control group(P<0.05); Lassitude, anorexia, clear night urine scores were significantly lower than the control group(P<0.05); The levels of UAE, BUN and Cr were significantly lower than those of the control group(P<0.05); The levels of TGF-1, beta 1, VEGF, MCP-1 and ANG II were significantly lower than those of the control group(P<0.05). Conclusion: Danhong injection combined with valsartan is well for chronic renal failure, which can improve the clinical symptoms, reduce urinary protein, improve the microcirculation of the kidney, and protect the renal function. It can significantly reduce the levels of serum TGF-β1, VEGF, MCP-1, ANG II, and alleviate the development of the disease.
|
|
|
|
|
|
[1] 刘金虹.丹红注射液的临床应用进展[J].中国药房,2014,25(23):2189~2191.
[2] 吴静,赵景宏,黄云剑,等.缬沙坦联合前列地尔注射液治疗慢性肾衰竭合并慢性心功能不全的疗效观察[J].医学综述,2014,20(16):3020~3022.
[3] 周成,王建刚,李震,等.丹红注射液治疗慢性肾衰竭维持性血液透析患者血瘀证65例临床分析[J].中国实验方剂学杂志,2015,21(16):167~170.
[4] 陈香美,倪兆慧,刘玉宁,等.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志,2015,35(9):1029~1033.
[5] 夏雪,邬元平.丹红注射液在慢性肾衰竭中的应用观察[J].北方药学,2015,12(11):29.
[6] 王小华,陈建平,金哲,等.肾衰宁片联合缬沙坦治疗慢性肾衰竭临床疗效[J].医学理论与实践,2015,28(23):3183~3185.
[7] 吴潇,陈宇.阿托伐他汀联合缬沙坦对慢性肾炎患者疗效及相关指标的影响[J].中国药房,2016,27(15):2065~2067.
[8] 卞志翔,顾慧益,张玉梅,等.丹红注射液联合前列地尔注射液治疗慢性肾脏病疗效观察[J].世界中西医结合杂志,2016,11(6):822~825.
[9] 刘青员,朱静和,李冬玲,等.前列地尔联合丹红注射液治疗早期糖尿病肾病疗效观察[J].基层医学论坛,2016,20(29):4045~4046.
[10] 鱼建平.缬沙坦联合贝前列素钠对高血压合并早期肾损伤患者肾功能、凝血功能以及内皮损伤的影响[J].海南医学院学报,2016,22(24):2989~2992. |
|
|
|
2018, Vol. 24 
